Nicolas Noulin
Overview
Explore the profile of Nicolas Noulin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith J, Kitt M, Bell A, Noulin N, Tzontcheva A, Seng M, et al.
Pulm Ther
. 2022 Aug;
8(3):297-310.
PMID: 35969360
Introduction: Available therapies for acute cough, a condition frequently caused by a viral upper respiratory tract infection (URTI), have shown limited evidence of efficacy. Gefapixant, a P2X3-receptor antagonist, has demonstrated...
2.
Killingley B, Mann A, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al.
Nat Med
. 2022 Apr;
28(5):1031-1041.
PMID: 35361992
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of cases and continues to circulate globally. To establish a novel SARS-CoV-2 human...
3.
Ahmad A, Eze K, Noulin N, Horvathova V, Murray B, Baillet M, et al.
N Engl J Med
. 2022 Feb;
386(7):655-666.
PMID: 35172056
Background: Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral...
4.
Sadoff J, De Paepe E, DeVincenzo J, Gymnopoulou E, Menten J, Murray B, et al.
J Infect Dis
. 2021 Jan;
226(3):396-406.
PMID: 33400792
Background: Respiratory syncytial virus (RSV) is a significant cause of severe lower respiratory tract disease in children and older adults, but has no approved vaccine. This study assessed the potential...
5.
Catchpole A, Fullen D, Noulin N, Mann A, Gilbert A, Lambkin-Williams R
BMC Res Notes
. 2018 Aug;
11(1):620.
PMID: 30157933
Objective: This manuscript aims to provide an overview of the unique considerations and best practice principles associated with the manufacture of human viral challenge agents. Results: Considerations are discussed on...
6.
Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert A
Respir Res
. 2018 Jun;
19(1):123.
PMID: 29929556
The Human Viral Challenge (HVC) model has, for many decades, helped in the understanding of respiratory viruses and their role in disease pathogenesis. In a controlled setting using small numbers...
7.
Fullen D, Noulin N, Catchpole A, Fathi H, Murray E, Mann A, et al.
PLoS One
. 2016 Jun;
11(6):e0157211.
PMID: 27280602
[This corrects the article DOI: 10.1371/journal.pone.0145902.].
8.
Fullen D, Noulin N, Catchpole A, Fathi H, Murray E, Mann A, et al.
PLoS One
. 2016 Jan;
11(1):e0145902.
PMID: 26761707
Background: Influenza and its associated diseases are a major cause of morbidity and mortality. The United States Advisory Committee on Immunization Practices recommends influenza vaccination for everyone over 6 months...
9.
Kelly G, Laxton C, Garelnabi M, Alton B, Addan F, Catchpole A, et al.
J Virol Methods
. 2015 Sep;
224:83-90.
PMID: 26335961
Retroscreen (hVIVO) have developed an RSV human viral challenge model (hVCM) for testing the efficacy of novel antiviral therapies by monitoring changes in viral load and symptoms. The integrated cycler...
10.
Mann A, Noulin N, Catchpole A, Stittelaar K, De Waal L, Veldhuis Kroeze E, et al.
PLoS One
. 2014 May;
9(5):e93761.
PMID: 24850536
We investigated the protective efficacy of two intranasal chitosan (CSN and TM-CSN) adjuvanted H5N1 Influenza vaccines against highly pathogenic avian Influenza (HPAI) intratracheal and intranasal challenge in a ferret model....